Artificial intelligence (AI) continues to dominate Wall Street as a transformative force, with investors divided between those bullish on its long-term potential and those wary of an impending bubble. For those seeking safer exposure to AI, investing in established, dividend-paying companies that leverage the technology without relying on it as their core business may be a prudent strategy. Two standout examples are Eli Lilly (LLY) and Medtronic (MDT).

Eli Lilly is thriving, particularly in the weight-loss drug market, with a remarkable 239.2% increase in dividends over the past decade. Its AI initiatives, such as developing advanced computational tools with Nvidia, could further enhance drug development efficiency and profitability. Meanwhile, Medtronic is integrating AI into its medical devices, improving product performance and reducing false alerts, while maintaining a strong revenue trajectory from recent product launches. Both companies offer a compelling mix of growth and income potential.

For investors looking to balance AI exposure with stability, Eli Lilly and Medtronic present attractive options. Dive deeper into their strategies and financials in the full article for a comprehensive analysis.

Source: fool.com